{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.12.', 'Appendix 12: CDC Classification for HIV-1 Infection (2014)', 'Note that the CD4+ T-lymphocyte count takes precedence over the CD4+ T-', 'lymphocyte percentage in HIV infection stages 1, 2, and 3. The CD4+ T-', 'lymphocyte percentage should only be considered if the count is missing.', 'HIV infection, stage 0', 'Indicates early HIV infection, inferred from a negative or indeterminate HIV test', 'result within 180 days of a positive result. The criteria for stage 0 supersede and are', 'independent of criteria used for other stages.', 'HIV infection, stage 1', 'Laboratory confirmation of HIV infection with no AIDS-defining condition, and', 'CD4+ T-lymphocyte count of >500 cells/L,', 'or', 'CD4+ T-lymphocyte percentage of total lymphocytes of >26%.', 'HIV infection, stage 2', 'Laboratory confirmation of HIV infection with no AIDS-defining condition, and', 'CD4+ T-lymphocyte count of 200 to 499 cells/L, or', 'CD4+ T-lymphocyte percentage of total lymphocytes of 14% to 25%.', 'HIV infection, stage 3 (AIDS)', 'Laboratory confirmation of HIV infection, and', 'CD4+ T-lymphocyte count of <200 cells/L, or', 'CD4+ T-lymphocyte percentage of total lymphocytes of <14%, or', 'Documentation of an AIDS-defining condition (see below).', 'Documentation of an AIDS-defining condition supersedes a CD4+ T-lymphocyte', 'count of >200 cells/L and a CD4+ T-lymphocyte percentage of total lymphocytes', 'of > 14%.', 'HIV infection, stage unknown', 'Laboratory confirmation of HIV infection, and', 'No information on CD4+ T-lymphocyte count or percentage, and', 'No information on presence of AIDS-defining conditions.', 'Stage-3-defining opportunistic illnesses in HIV infection', 'Candidiasis of bronchi, trachea, or lungs', 'Candidiasis of oesophagus', 'Cervical cancer, invasive', 'Coccidioidomycosis, disseminated or extrapulmonary', '153']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Cryptococcosis, extrapulmonary', \"Cryptosporidiosis, chronic intestinal (>1 month's duration)\", 'Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month', 'Cytomegalovirus retinitis (with loss of vision)', 'Encephalopathy, HIV-related', \"Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or\", 'oesophagitis (onset at age > 1 month)', 'Histoplasmosis, disseminated or extrapulmonary', \"Isosporiasis, chronic intestinal (>1 month's duration)\", \"Kaposi's sarcoma\", \"Lymphoma, Burkitt's (or equivalent term)\", 'Lymphoma, immunoblastic (or equivalent term)', 'Lymphoma, primary, of brain', 'Mycobacterium avium complex or Mycobacterium kansasii, disseminated or', 'extrapulmonary', 'Mycobacterium tuberculosis of any site, pulmonary, disseminated or extrapulmonary', 'Mycobacterium, other species or unidentified species, disseminated or', 'extrapulmonary', 'Pneumocystis jirovecii pneumonia', 'Pneumonia, recurrent', 'Progressive multifocal leukoencephalopathy', 'Salmonella septicaemia, recurrent', 'Toxoplasmosis of brain, onset at age > 1 month', 'Wasting syndrome attributed to HIV.', '154']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.13.', 'Appendix 13: Country-specific requirements', 'United Kingdom', 'This requirement has been included based on requests from the Medicines and Healthcare', 'products Regulatory Agency (MHRA) to include information on the specific duration of', 'the Continuation Phase/Study Intervention for similar Phase III trials being conducted', 'with dolutegravir.', 'Study Duration', 'In this study, the date of last study intervention administration in the UK will be', 'determined by the completion of the 52 week randomized phase of the study for the last', 'UK participant enrolled (it will not be determined by the completion of the Continuation', 'Phase). The last participant will be enrolled by Q1 2020/Q2 2020, and hence the last', 'study intervention administration will occur by Q1 2021/Q2 2021. (Note: The', 'Continuation Phase is intended to provide participants receiving DTG/3TC FDC with', 'post-study access to DTG/3TC FDC until DTG plus 3TC is approved as a 2-drug regimen', 'in their local countries. For participants in the UK, the Continuation Phase is not', 'anticipated to be required as the 2-drug regimen of DTG/3TC FDC is anticipated to be', 'approved by Q3/Q4 2020.', 'Sweden and Denmark', 'A country specific protocol amendment, 208090 Amendment 03/SWE-DEN-1 was', 'previously published on 29-July-2019 for Sweden and Denmark to remove all references', 'to the Continuation Phase. Participants in Sweden and Denmark in both treatment arms', 'will finish the study at Week 52. This amendment was a regulatory requirement for', \"Sweden and Denmark to update the protocol with a clear time for the study's conclusion\", 'based on scientific basis without any reference to market approval. Protocol text in the', 'current global protocol amendment 04 related to the continuation phase does not apply to', 'Sweden and Denmark. A summary of sections that reference the continuation phase is', 'included here:', 'Section 1: Protocol Summary, Section 1.2: Study Schematic,', 'Section 1.3: Schedule of Activities and footnotes', 'Section 2.3.1: Risk Assessment,', 'Section 3: Objectives and Endpoints', 'Section 4.1: Overall Design', 'Section 4.3: Participant and Study Completion', 'Section 6.7: Concomitant Therapy', 'Section 6.8: Treatment after the end of the study', 'Section 7.1: Discontinuation of study intervention', 'China', 'A country specific protocol amendment, 208090 Amendment 03/CHI-1, was previously', 'published on 31-May-2019 for China based on a requirement to perform all laboratory', '155']\n\n###\n\n", "completion": "END"}